Drug delivery device

Claim 2

A composition of matter for oral, rectal or vaginal administration comprising a core tablet or granules of a therapeutically effective amount of at least one therapeutic agent selected from the group consisting of a B-blocker, antimicrobial, steroidal anti-inflammatory, non-steroidal anti-inflammatory, antihypertensive, sex hormone, muscle relaxant, antiasthma, antiemetic, antidepressant, diuretic and vasodilator, and a polyvinyl alcohol coating on said core tablet or granules, the amount of said therapeutic agent and polyvinyl alcohol constituting from 0.1 to 500 mg per composition and 1 to 15% of total composition weight, respectively.

Claim 3

The composition of Claim 1, wherein said B-blocker is selected from the group consisting of timolol, bupranolol, timolol aleate, or propranolol; said antimicrobial is selected from the group consisting of lincomycin, tetracycline, erythromycin, penicillin, penicillin G, cefoxitin, streptomycin, carbenicillin, cephapirin, cephalosporin C or cephanone; said steroidal anti-inflammatory is selected from the group consisting of hydrocortisone, hydrocortisone 21-acetate, betamethasone, betamethasone valerate, prednisolone, prednisolone 21-phosphate, cortisone acetate, fludrocortisone acetate, triamcinolone or nivazol; said non-steroidal anti-inflammatory is selected from the group consisting of indomethacin, naproxen, fenoprofen, sulindac, ibuprofen, diflunisal, aminopyrine, antipyrine, nimazole, tramadol, fluprofen or demecolcine; said antihypertensive is selected from the group consisting of methyldopa, clonidine and antianginas such as propranolol hydrochloride, erythrityl tetranitrate or dioxyline phosphate; said sex hormone is selected from the group consisting of estrogen, progestin, androgen, testosterone or progesterone; said muscle relaxant is selected from the group consisting of succinylcholine chloride, baclofen, dantrolene sodium, metaxalone, cyclobenzoprine hydrochloride or diazepam; said anti-asthma is selected from the group consisting of theophylline,terbutaline sulfate, dyphyline and guaifenesin, or cromoglycic acid; said antiemetic is selected from the group consisting of chlorpromazine, dimenhydrinate or pipamazine; said antidepressant is selected from the group consisting of protriptyline hydrochloride, chlordiazepoxide hydrochloride, amitriptyline, or doxepin hydrochloride; said diuretic is selected from the group consisting of aldactone, diuril or hydrochlorothiazide; and said vasodilators such as nitroglycerin, erythritol tetranitrate, isosorbide dinitrate, mannitol hexanitrate, pentaerythrityl tetranitrate, papaverine and dipyridamole, or mixture thereof and wherein said polyvinyl alcohol constitutes from 2 to 5% of the composition weight.

Claim 4

The composition of Claim 2 wherein said β-blocker is timolol maleate, said antimicrobial is cefoxitin, said steroidal anti-inflammatory is hydrocortisone, said non-steroidal anti-inflammatory is indomethacin, said antihypertensive is methyldopa, said sex hormone is estrogen and said anti-depressant is amitriptyline.

Claim 5

The composition of Claim 1, wherein said therapeutic agent is a mixture of timolol maleate and hydrochlorothiazide.

Claim 6

The composition of Claim 1, wherein said therapeutic agent is a mixture of hydrocortisone and indomethacin.

Claim 7

The composition of Claim 1, wherein said therapeutic agent is a mixture of indomethacin and cyclobenzaprine.

Claim 8

The composition of Claim 1, wherein said therapeutic agent is a mixture of methyldopa and hydrochlorothiazide or a mixture of amitriptyline and bupranolol.

Claim 9

The composition of Claim 1 in oral or suppository form.

Claim 10

The composition of Claim 1 further comprising at least one pharmaceutically acceptable buffer.